Gastrooesophageal cancer+1
RecruitingStudy on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease
Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease
- Disease:Gastrooesophageal cancerGastric cancer
- Substances:Calcium FolinateCapecitabine+3
Italy- Participants:18–64 years · 65+ years
- Substances:Calcium Folinate
- Sponsor:Gruppo Oncologico Del Nord Ovest











